Dublin, Feb. 08, 2019 (GLOBE NEWSWIRE) -- The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018" report has been added to ResearchAndMarkets.com's offering.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2012 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
In addition, a comprehensive appendix of all preclinical deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Report scope
- Trends in preclinical stage dealmaking in the biopharma industry since 2012
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,000 preclinical stage deals
- The leading preclinical stage deals by value since 2012
- Most active preclinical stage dealmakers since 2012
- The leading preclinical stage partnering resources
Available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
The report includes deals announced by hundreds of life science companies including big pharma such as
- Abbott
- Abbvie
- Actavis
- Amgen
- Astellas
- AstraZeneca
- Baxter
- Bayer
- Biogen Idec
- BMS
- Celgene
- Eisai
- Eli Lilly
- Gilead
- GSK
- J&J
- Kyowa Hakko
- Merck
- Mitsubishi
- Mylan
- Novartis
- Pfizer
- Roche
- Sanofi
- Shire
- Takeda
- Teva
- Valeant
For more information about this report visit https://www.researchandmarkets.com/research/j3gt24/global_pharma_and?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.